HIV儿童口服更昔洛韦的药代动力学和耐受性研究-猫眼课题宝

HIV儿童口服更昔洛韦的药代动力学和耐受性研究

批准号：

6282257

负责人：

RUSSEL B VAN DYKE

金额：

$1.97万

依托单位：

TULANE UNIVERSITY OF LOUISIANA

依托单位国家：

美国

项目类别：

财政年份：

1997

资助国家：

美国

项目状态：

已结题

起止时间：

1997-12-01 至 1999-06-30

来源：

https://reporter.nih.gov/project-details/6282257

关键词：

AIDS therapy adolescence (12-20) antiviral agents child (0-11) clinical research cytomegalovirus dosage drug screening /evaluation ganciclovir human subject microorganism disease chemotherapy opportunistic infections oral administration pediatric AIDS pediatric pharmacology

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

The purpose of ACTG 226 is to determine the pharmacokinetics, maximum tolerated dose and long-term safety of oral ganciclovir in HIV-infected infants, children and adolescents with CMV infection or quiescent CMV disease. This is a Phase I, dose-escalating, long-term tolerance study of oral ganciclovir. It is designed to evaluate the pharmacokinetics and to determine the MTD of oral ganciclovir. The study will primarily determine pharmacokinetic parameters of the oral suspension of ganciclovir. Data on the capsule formulation for older children and adolescents will also be obtained at the maximum tolerated dose.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文